Molecular themes in oncogenesis

Cell

Volumn 64, Issue 2, 1991, Pages 235-248

  Bishop, J Michael ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER INHIBITION; CARCINOGENESIS; HUMAN; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE; REVIEW; SUPPRESSOR GENE;

ANIMAL; CELL TRANSFORMATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMAN; MUTATION; NEOPLASMS; ONCOGENES; PROTO-ONCOGENES; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0026010995     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/0092-8674(91)90636-D     Document Type: Review

References (190)

1. Molecular mimicry of growth factors by products of tumor viruses
2. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
3. A 3′ truncation of Myc caused by chromosomal translocation in a human T-cell leukemia increases mRNA stability
4. Oncogene amplification in tumor cells
5. Requirement of the Drosophila raf homologue for torso function
6. Identifying environmental chemicals causing mutations and cancer
7. Too many rodent carcinogens: mitogenesis increases mutagenesis
8. DNA replication origin and transcriptional enhancer in c-myc gene share the c-myc protein binding sequences
9. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas
10. Suppression of human colorectal carcinoma cell growth by wild-type p53
11. Ras genes
12. Structure and expression of the murine retinoblastoma gene and characterization of its encoded protein
13. The molecular genetics of cancer
14. Oncogenes and clinical cancer
15. Functions and origins of retroviral transforming genes
16. Localization of the gene for familial adenomatous polyposis on chromosome 5
17. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated Rb gene
18. Tumor angiogenesis: the role of oncogenes and tumor suppressor genes
19. G proteins and cAMP: discovery of a new oncogene in pituitary tumours?
20. The GTPase superfamily. I. A conserved switch for diverse cell functions
21. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the ras cyclic AMP pathway
22. The retinoblastoma protein is phosphorylayted during specific phases of the cell cycle
23. The origin of human cancers
24. Oncogenes and signal transduction
25. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations
26. c-src during fibroblast mitosis
27. Phosphorylation of the retinoblastoma gene product is modulated during cell cycle and cellular diferentiation
28. Cell proliferation in carcinoma-genesis
29. The myc oncogene: its role in transformation and differentiation
30. The Src family of protein-tyrosine kinases
31. A new cytokine receptor superfamily
32. Protein encoded by v-erbA functions as a thyroid hormone receptor antagonist
33. Proliferative patterns in colonic mucosa in familial polyposis
34. ras
35. ras upon T-cell activity
36. Experimental models and biological mechanisms for tumor promotion
37. Increased mutational rates in Chinese hamster ovary cells serially selected for drug resistance
38. Parental origin of mutations of the retinoblastoma gene
39. Oncogenes of DNA Tumor Viruses: Papovaviruses
40. Protein serine/threonine kinase
41. Wild-type p53 can inhibit oncogene-mediated focus formation
42. Phosphorylation of GAP and GAP-associated proteins by transforming and mitogenic tyrosine kinases
43. A genetic model for colorectal tumorigenesis
44. Identification of a chromosome-18Q gene that is altered in colorectal cancers
45. Genetic control of cancer metastasis
46. Presence of a potent transcription activating sequence in the p53 protein
47. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastoma: correlation with N-myc amplification
48. Inhibition of GTPase activating protein stimulation of ras-p21 GTPase by the Krev-1 gene product
49. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma
50. The transforming activity of the chicken c-myc gene can be potentiated by mutations
51. Structural evidence for the authenticity of the human retinoblastoma gene
52. Evolution of B-cell malignancy, pre-B-cell leukemia resulting from Myc activation in a B-cell neoplasm with a rearranged BCL2 gene
53. Nf-κB, KBF1, dorsal and related matters
54. Hamster cells with increased rates of DNA amplification: a new phenotype
55. + protein kinase regulates entry into mitosis
56. Leukemia as a multistep process: studies with avina retroviruses containing two oncogenes
57. Translocation of a store of maternal cytoplasmic c-myc protein into nuclei during early development
58. An internal deletion within an 11p13 zinc finger gene contributes to the development of Wilms' tumor
59. Oncogene activation by chromosome translocation in human malignancy
60. Dissecting multistep tumorigenesis in transgenic mice
61. Molecular aspects of the metastatic cascade
62. Telomere reduction in human colorectal carcinoma and with ageing
63. Inhibition of the ras-P21 GTPase-activating protein-stimulated GTPase activity of c-Ha-ras-P21 by SMG-P21 having the same putative effector domain as ras-P21S
64. erb-B, growth factor receptor turned oncogene
65. Effects of the tumour promoter okadaic acid on intracellular protein phosphorylation and metabolism
66. Activation of a cellular oncogene by promoter insertion in ALV-induced lymphoid leukosis
67. Functional inactivation of genes by dominant negative mutations
68. Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation
69. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells
70. Overproduction of protein kinase C causes disordered growth control in rat fibroblasts
71. Retinoblastoma growth suppressor and a 300kDa protein appear to regulate cellular DNA synthesis
72. Cells that overproduce protein kinase C are more susceptible to transformation by an activated H-ras oncogene
73. Glucocorticoid regulation of the Ha-MuSV p21 gene conferred by sequences from mouse mammary tumor virus
74. Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells
75. Under arrest in the cell cycle
76. A tail of two src's: mutatis mutandis
77. A thousand and one protein kinases
78. Oncogene products in the cytoplasm: the protein kinases
79. Protein-tyrosine phosphatases: the other side of the coin
80. Cooperation between oncogenes
81. Paternal origin of new mutations in Von Recklinghausen neurofibromatosis
82. Hormonal regulation of the Rous sarcoma src gene via a heterologous promoter defines a threshold dose for cellular transformation
83. PDGF β-receptor stimulates tyrosine phosphorylation of GAP and association of GAP with a signaling complex
84. The protein kinase C family, heterogeneity and its implications
85. Differential phosphorylation of c-Abl in cell cycle determined by cdc2 kinase and phosphatase activity
86. A ras-related gene with transformation suppressor activity
87. Genetics of human cancer
88. Role of a tumor-suppressor gene in the negative control of anchorage-independent growth of Syrian hamster cells
89. Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules
90. Functional cloning of a nucleoside diphosphate kinase from Dictyostelium discoideum
91. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes
92. Cellular oncogenes and multistep carcinogenesis
93. s and stimulate adenylyl cyclase in human pituitary tumours
94. p53: oncogene or anti-oncogene
95. High incidence of lung, bone and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene
96. Human retinoblastoma susceptibility gene: cloning, identification and sequence
97. The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses
98. Tumor suppressor genes, the p53 and retinoblastoma sensitivity genes and gene products
99. Oncogenic conversion by regulatory changes in transcription factors
100. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation
101. Biomarkers of increased susceptibility of gastrointestinal cancer, new application to studies of cancer prevention in human subjects
102. Pathogenesis of Burkitt's lymphoma: expression of an activated c-myc oncogene causes the tumorigenic conversion of EBV-infected human B lymphoblasts
103. The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T
104. Tyrosine kinase activity and transformation potency of BCR-ABL oncogene products
105. Myb DNA binding inhibited by phosphorylation at a site deleted during oncogenic activation
106. A protein product of the Drosophila recessive tumor gene 1 (2) giant gl potentially has cell adhesion properties
107. Two G protein oncogenes in human endocrine tumors
108. Tumor suppressor genes
109. Tumorigenicity of SEWA murine cells correlates with degree of c-myc amplification
110. Gasp, not just another oncogene
111. Molecular cloning of lethal(2)giant larvae, a recessive oncogene of Drosophila melanogaster
112. Tumor progression
113. A mutant protein kinase-C that can transform fibroblasts
114. The structure of mutation in mammalian cells
115. Cell cycle dependent regulation of phosphorylation of the human retinoblastoma gene product
116. cdc2 in transformed cells
117. cdc2-associated protein kinase
118. Signal transduction from membrane to cytoplasm: growth factors and membrane-bound oncogene products increase Raf-1 phosphorylation and associated protein kinase activity
119. Direct activation of the serine/threonine kinase activity of Raf-1 through tyrosine phosphorylation by the PDGF β-receptor
120. Requirements for ras proto-oncogene function during serum-stimulated growth of NIH 3T3 cells
121. Mechanisms of p53 loss in human sarcomas
122. Genetic repertory of human neoplasia
123. The cell cycle as a cdc2 cycle
124. Induction of immortality is an early event in malignant transformation of mammalian cells by carcinogens
125. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high-risk families
126. Mutations in the p53 gene occur in diverse human tumour types
127. cdc2 homologues
128. Mechanisms of tumor progression
129. 1 events and regulation of cell proliferation
130. TGF-β1 inhibition of c-myc transcription and growth in keratinocytes is abrogated by viral transforming proteins with pRB binding domains
131. Is imprinting to blame?
132. Inherited predisposition to cancer
133. Neoplastic transformation and tumorigenesis by the human protooncogene Mtc
134. The raf oncogene
135. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene
136. Negative regulation of human c-fos expression by the retinoblastoma gene product
137. Serum-inducible genes
138. Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development
139. The challenge to man of the neoplastic cell
140. A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potential
141. Adenovirus early region 1A enables viral and cellular transforming genes to transform primary cells in culture
142. Function of c-mos proto-oncogene product in meiotic maturation in Xenopous oocytes
143. The product of the Mos proto-oncogene as a candidate initiator for oocyte maturation
144. The c-mos proto-oncogene product is a cytostatic factor responsible for meiotic arrest in vertebrate eggs
145. Tumor suppressor genes: the puzzle and the promise
146. Delineation of 3 functional domains of the transcriptional activator encoded by the c-myb protooncogene
147. Repression of transcription mediated at a thyroid hormone response element by the v-erb-A oncogene product
148. Genome imprinting, cellular mosaicism and carcinogenesis
149. Genes specifically expressed at growth arrest of mammalian cells
150. Amplification of cellular oncogenes: a predictor of clinical outcome in human cancer
151. Genetic and epigenetic losses of heterozygosity in cancer predisposition and progression
152. The mos oncogene
153. c-src at the sites phosphorylated during fibroblast mitosis
154. Requirement for c-ras proteins during viral oncogene transformation
155. Malignant transformation of early passage rodent cells by a single mutated human oncogene
156. The block to transcription elongation is promoter dependent in normal and Burkitt's lymphoma c-myc alleles
157. The Drosophila gene torso encodes a putative receptor tyrosine kinase
158. Recent progress in understanding mechanisms of mammalian DNA amplification
159. Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts
160. cdc2 in mammalian cells: implications for cell cycle control and oncogenesis
161. Calyculin-A, an inhibitor of protein phosphatases, a potent tumor promoter on CD-1 mouse skin
162. Ras oncogenes in chemical carcinogenesis
163. Transformation of murine myelomonocytic cells by myc: point mutations in v-myc contribute synergistically to transforming potential
164. p53, a frequent target for genetic abnormalities in lung cancer
165. Evidence for multiple steps in neoplastic transformation of normal and preneoplastic Syrian hamster embryo cells following transfection with harvey murine sarcoma virus oncogene (v-Ha-ras)
166. Differences in the rates of gene amplification in nontumorigenic and tumorigenic cell lines as measured by Luria-Delbruck fluctuation analysis
167. Preferential mutation of paternally derived RB gene as the initial event in sporadic osteosarcoma
168. A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants
169. Signal transduction by receptors with tyrosine kinase activity
170. s and adenylate cyclase activity in human GH-secreting pituitary adenomas
171. The mouse type IV c-abl gene product is a nuclear protein, and activation of transforming ability is associated with cytoplasmic localization
172. An historical overview of oncogenes
173. N-Myc expression switched off and class I human leukocyte antigen expression switched on after somatic cell fusion of neuroblastoma cells
174. Allelotype of colorectal carcinomas
175. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients
176. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma
177. Oncogene v-jun modulates DNA replication
178. The retinoblastoma gene and cell growth control
179. cdc28 protein kinase
180. Molecular cloning of the Lethal(1)Discs Large-1 oncogene of Drosophila
181. Activation of the feline c-fms proto-oncogene: multiple alterations are required to generate a fully transformed phenotype
182. DNA amplification is rare in normal human cells
183. The neurofibromatosis type 1 gene encodes a protein related to GAP
184. Chromosomal rearrangements, genes, and fragile sites in cancer: clinical and biologic implications
185. Suppression of c-ras transformation by GTPase-activating protein
186. A novel viral oncogene with structural similarity to phospholipase C